Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases
AssigneeBristol-Myers Squibb Company
InventorsMaria Jure-Kunkel, Jon Marc Wigginton, Ashok Kumar Gupta
Life of this patent
Estimating the term…
Abstract
Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.
Claims13
A method for the treatment of proliferative diseases, including cancer, which comprises administration to a mammal in need thereof a synergistically, therapeutically effective amount of an anti-CTLA-4 agent with methyl {5-[2-chloro-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl]-1H-benzimidazol-2-yl}carbamate.
A method for the treatment of proliferative diseases, including cancer, which comprises administration to a mammal in need thereof a synergistically, therapeutically effective amount of an anti-CTLA-4 agent with PLX-4032.
Dependencies are inferred from the claim text.